Optimalisatie van de werkingsprocessen van het Bijzonder ... - KCE

More documents

Recommendations

Info

74 Special Solidarity Fund KCE Reports 133 Figure 13: Drug reimbursement system the Netherlands Source: KCE, Beleid voor Weesziekten en Weesgeneesmiddelen, KCE reports 112 A, 2009 For EU-registered orphan drugs for which a Market Authorisation exists, but that are not listed in the GVS - for example because they are still in an experimental stage or due to a lack of ‘added therapeutic value’ –, the Minister of health developed a specific subsidy programme for the reimbursement of orphan drugs that are prescribed extra muros. The aim of the subsidy programme is to ensure that the assessment procedure to which an orphan drug is imposed, does not impede the reimbursement of the orphan drug. Medicines that have been granted Market Authorization somewhere else, but not in the Netherlands, require a positive reply of the Head Inspector on an import request by a healthcare provider. In case of a positive advice, reimbursement takes place following the intra muros or extra muros provisions. For drugs with no Market Authorisation, one could distinguish different options: • An insured suffers from a disease with prevalence in the Netherlands not exceeding 1 in 150.000 inhabitants and the prescription of a nonregistered drug is considered as ‘rational’: the same reimbursements rules are applicable, as for drugs with non-Dutch Market Authorization. • An insured suffers from a disease with prevalence in the Netherlands exceeding 1 in 150.000 inhabitants: o The drug is not subjected to clinical research: the same reimbursements rules could be applicable, as for drugs with a non- Dutch Market Authorization. o The drug is subjected to clinical research, in which the insured could take part. After the clinical trial, pharmaceutical companies often continue to provide these drugs to the test persons if the drug turned out to be effective. o Finally, if the insured does not meet the criteria for participation in clinical research, he could rely on a ‘compassionate use’ programme in exceptional cases. Compassionate use is possible if: o There is a declaration of the healthcare provider (GP, specialist...); • There is no alternative drug on the market and is waiting a MA. The following figure illustrates the different reimbursement options for a medicine for rare diseases.
KCE Reports 133 Special Solidarity Fund 75 Figure 14: Reimbursement of medicines for rare diseases in the Netherlands Source: Steering Committee Orphan Drugs, Beschikbaarheid van Geneesmiddelen voor Zeldzame Ziekten, 2009
Page 1 and 2:
Optimalisatie van de werkingsproces
Page 3 and 4:
Optimalisatie van de werkingsproces
Page 5 and 6:
KCE reports 133A Bijzonder Solidari
Page 7 and 8:
Page 9 and 10:
Page 11 and 12:
Page 13 and 14:
Page 15 and 16:
Page 17:
Page 20 and 21:
2 Special Solidarity Fund KCE Repor
Page 22 and 23:
Page 24 and 25:
Page 26 and 27:
Page 28 and 29:
10 Special Solidarity Fund KCE Repo
Page 30 and 31:
Page 32 and 33:
Page 34 and 35:
Page 36 and 37:
Page 38 and 39:
Page 40 and 41:
Page 42 and 43: 24 Special Solidarity Fund KCE Repo
Page 118 and 119: 100 Special Solidarity Fund KCE Rep
Page 142 and 143:
124 Special Solidarity Fund KCE Rep
Page 144 and 145:
Page 146 and 147:
Page 148 and 149:
Page 150 and 151:
Page 152 and 153:
Page 154 and 155:
Page 156 and 157:
Page 158 and 159:
Page 160 and 161:
Page 162 and 163:
Page 164 and 165:
Page 166 and 167:
Page 168 and 169:
Page 170 and 171:
Page 172 and 173:
Page 174 and 175:
Page 176 and 177:
Page 178 and 179:
Page 180 and 181:
Page 182 and 183:
Page 184 and 185:
Page 186 and 187:
Page 188 and 189:
Page 190 and 191:
Page 192 and 193:
Page 194 and 195:
Page 196 and 197:
Page 198 and 199:
Page 200 and 201:
Page 202 and 203:
Page 204 and 205:
Page 206 and 207:
Page 208 and 209:
Page 210 and 211:
Page 212 and 213:
Page 214 and 215:
Page 216 and 217:
Page 218 and 219:
Page 220 and 221:
Page 222 and 223:
Page 224 and 225:
Page 226 and 227:
Page 228 and 229:
Page 230 and 231:
Wettelijk depot : D/2010/10.273/44
Page 232 and 233:
37. HTA Magnetische Resonantie Beel
Page 234:
108. Tiotropium in de behandeling v
show all

Optimalisatie van de werkingsprocessen van het Bijzonder ... - KCE

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?